MedMen Q4 Earnings: Burns $316M cash in Fiscal 2019

After the bell, Medmen Enterprises (CSE: MMEN) released their 4th quarter earnings. The headline for the quarter in our opinion is the combined annual cash burn of $316.87M (combined operating and investing cash flows).

When I breakdown quarterly numbers, I like to look at some of the key data on a quarter over quarter basis:

 Q4Q3% change
Revenue42.036.614.7%
Gross Margin16.015.53.1%
Gross Marin %38.1%42.4% 
System Wide Revenue42.036.614.8%
G&A Expense51.361.3-16.2%
Sales and Marketing Expense7.46.710.6%
Net Loss-82.9-63.131.5%
Operating Cash Flow-51.9-59.2-12.4%
Investing Cash Flow-41.127.5 
Adjusted EBITDA-39.4-42.6-7.4%

From The Conference Call

  • There remains $125M of cash on the facility from Gotham Green, which they are planning to restructure to current market conditions.
  • Targeting 30 stores in California by the end of next fiscal year.
  • The companies long run goal is 60% retail gross margins.
  • Majority of cash burn moving forward is on the operating side, ie. ramping stores, not on building facilities.
  • Main focus is on California, Florida and New York.
  • Company is targeting a full 30% reduction in SG&A.

Breakdown of Expenses

From the notes, we can see some of the significant line items on SG&A. Where it is interesting to note the nearly $8M spent on travel and entertainment.

Also of note, the company’s executives received around $21M in share-based compensation, which is likely comprised of way out of the money options that will never be exercised.

On the cash concerns. The company has nearly $90M in convertibles (which are way out of the money), plus another $70M in accounts and notes payable all due in less than one year.

Overall Thoughts On The Quarter

Medmen remains one of the most interesting companies in the cannabis public markets. The company has invested more money into building out brands than anyone else in the space. They are the market leader, in a highly fragmented state that often sets the tone for brands across the US.

Overall, the company only grew topline revenue by 15% quarter over quarter and continues to burn cash at an alarming rate. Investors will want to keep a keen eye on the companies ability to raise cash over the next few quarters. Medmen tells us they had gross margins of 50% vs. 53% last quarter for retail, which we cannot assess because this a non-IFRS number and the gross margins reflected on the income statement is actually sub 40%. At the time of the conference call, the company still had yet to publish the full statements on sedar.


Information for this briefing was found via Sedar and MedMen. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

First Majestic Posts Record Cash Flows In Q1 As Production Costs Fall

Brazil Potash Secures Funding In Support Of US$2.5 Billion Autozales Project

Related News

Sundial Reports Q2 Earnings with Significant Related Party Transactions

This morning Sundial Farms (NASDAQ: SNDL) reported their second quarter of financial earnings, here is...

Wednesday, August 14, 2019, 03:45:17 PM

#Potstocks Earnings Week May 29 – 31, 2019

For those that closely follow the potstocks sector, you’re likely aware that the week ahead...

Monday, May 27, 2019, 06:30:25 AM

GameStop Reports 8.5% Drop in Revenue in Q3, with Substantial Adjusted EBITDA Loss; Valuation Remains Difficult to Understand

After the regular market close on December 7, GameStop Corp. (NYSE: GME) reported a second...

Sunday, December 11, 2022, 10:32:00 AM

iAnthus Hits $120M Pro-Forma Revenue Run Rate

This evening iAnthus Capital Holdings (CSE: IAN) released quarterly earnings. The company showed strong top-line...

Wednesday, November 20, 2019, 08:08:18 PM

Medmen: Canaccord Reiterates $0 Price Target, Sell Rating

On December 7th, Medmen Enterprises’ (CSE: MMEN) reported first-quarter fiscal 2021 financial results. Medmen reported...

Wednesday, December 9, 2020, 10:50:51 AM